Recombinant Human GSK3A Protein (S2-S483), Tag Free

• Cat.No.: GSK3A-0315H
• Product Overview: Recombinant Human GG-GSK3α(S2-S483 end) Protein was expressed in Insect cell.

Specification

• Description: Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), CTNNB1/beta-catenin, APC and AXIN1. Requires primed phosphorylation of the majority of its substrates. Contributes to insulin regulation of glycogen synthesis by phosphorylating and inhibiting GYS1 activity and hence glycogen synthesis. Regulates glycogen metabolism in liver, but not in muscle. May also mediate the development of insulin resistance by regulating activation of transcription factors. In Wnt signaling, regulates the level and transcriptional activity of nuclear CTNNB1/beta-catenin. Facilitates amyloid precursor protein (APP) processing and the generation of APP-derived amyloid plaques found in Alzheimer disease. May be involved in the regulation of replication in pancreatic beta-cells. Is necessary for the establishment of neuronal polarity and axon outgrowth. Through phosphorylation of the anti-apoptotic protein MCL1, may control cell apoptosis in response to growth factors deprivation. Acts as a regulator of autophagy by mediating phosphorylation of KAT5/TIP60 under starvation conditions, leading to activate KAT5/TIP60 acetyltransferase activity and promote acetylation of key autophagy regulators, such as ULK1 and RUBCNL/Pacer. Negatively regulates extrinsic apoptotic signaling pathway via death domain receptors. Promotes the formation of an anti-apoptotic complex, made of DDX3X, BRIC2 and GSK3B, at death receptors, including TNFRSF10B. The anti-apoptotic function is most effective with weak apoptotic signals and can be overcome by stronger stimulation.
• Source: Insect cell
• Species: Human
• Tag: Non
• Form: Liquid
• Protein length: S2-S483
• Endotoxin: < 0.01 EU per μg of the protein
• Purity: 90%
• Stability: Samples are stable for up to twelve months from date of receipt at -20 to -80 centigrade.
• Storage: Store it under sterile conditions at -20 to -80 centigrade. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Storage Buffer: Supplied as sterile 50 mM Tris-HCl (pH7.5), 200 mM NaCl, 20% glycerol
• Shipping: It is shipped out with blue ice.

Gene Information

• Gene Name: GSK3A glycogen synthase kinase 3 alpha [ Homo sapiens (human) ]
• Official Symbol: GSK3A
• Synonyms: GSK3A; glycogen synthase kinase 3 alpha; glycogen synthase kinase-3 alpha; GSK-3 alpha; serine/threonine-protein kinase GSK3A; DKFZp686D0638
• Gene ID: 2931
• mRNA Refseq: NM_019884
• Protein Refseq: NP_063937
• MIM: 606784
• UniProt ID: P49840

Reviews

08/12/2020

Its high purity and integrity ensure reliable and reproducible results, minimizing any potential variability in my experimental outcomes.

09/18/2019

This aspect is crucial in maintaining the scientific rigor of my studies and strengthens the validity of my research findings.

04/10/2019

the manufacturer's commitment to continuous improvement and innovation is evident in their constant efforts to enhance the GSK3A protein.

Q&As

In what ways is GSK3A linked to diabetes?

GSK3A is implicated in insulin signaling and glucose metabolism, and its dysregulation is associated with insulin resistance, a key feature of type 2 diabetes.

Can GSK3A inhibitors have an impact on mood disorders?

Yes, GSK3A is implicated in pathways associated with mood regulation, and inhibitors are being investigated for their potential in treating mood disorders.

Are there GSK3A modulators being explored for anti-inflammatory therapies?

Yes, there is ongoing research to develop GSK3A modulators as potential anti-inflammatory agents.

How does GSK3A contribute to inflammatory conditions?

GSK3A is involved in inflammatory signaling pathways, and its activity is linked to the regulation of inflammatory responses.

Are there any clinical interventions targeting GSK3A for diabetes management?

Researchers are investigating the potential of GSK3A inhibitors to improve insulin sensitivity and glucose homeostasis in diabetes.